Table 2.
Response type | All patients, n | Sensitive baseline mutation,* n (%) | Insensitive baseline mutation,† n (%) | Imatinib-resistant, n (%) | Imatinib-intolerant, n (%) |
---|---|---|---|---|---|
Slow (monophasic) |
65 |
21 (32.3) |
18 (27.7) |
58 (89.2) |
7 (10.8) |
Fast (biphasic) | 58 | 18 (31.0) | 2 (3.4) | 42 (72.4) | 16 (27.6) |
* Half maximal inhibitory concentration (IC50) ≤ 150 nm.
† IC50 > 150 nm; Y253H, E255V/K, F359V/C.